Crossmark

Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List

Crossref DOI link: https://doi.org/10.1186/s12913-019-3937-0

Published Online: 2019-02-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Wenbin

Shi, Lizheng

Sawhney, Monika

Gu, Xiaoli

Chen, Yingyao
Funding

Funding for this research was provided by:

Fujian Education & Scientific Research Project for Young Scholars (JA14140S)

China Medical Board (11-067)

National Natural Science Foundation of China (71704026)
License Information

Text and Data Mining valid from 2019-02-11
More Information

Article History

Received: 24 October 2018

Accepted: 29 January 2019

First Online: 11 February 2019

Ethics approval and consent to participate

: The research does not report on or involve the use of any animal or human data or tissue. Therefore, the ethics approval and consent to participate are not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.